SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-081304
Filing Date
2024-09-24
Accepted
2024-09-24 11:55:10
Documents
15
Period of Report
2024-09-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0215492-8k_immucell.htm   iXBRL 8-K 31028
2 AMENDED AND RESTATED BY-LAWS OF IMMUCELL CORPORATION, AMENDED THROUGH SEPTEMBER ea021549201ex3-2_immucell.htm EX-3.2 115970
3 FIFTH AMENDMENT OF INDENTURE OF LEASE FOR PREMISES LOCATED IN PORTLAND, MAINE BE ea021549201ex10-1_immucell.htm EX-10.1 16329
  Complete submission text file 0001213900-24-081304.txt   364612

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20240920.xsd EX-101.SCH 3015
5 XBRL LABEL FILE iccc-20240920_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE iccc-20240920_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0215492-8k_immucell_htm.xml XML 3675
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 241318461
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)